The pharmaceutical industry is undergoing significant transformation, driven by the increasing integration of artificial intelligence (AI) in drug research and development (R&D). This transformation is evidenced by significant advancements such as the nomination of Rentosertib, the first AI-designed drug, by USAN. Major players like Sanofi are leveraging AI to optimize drug target discovery, while AI is also revolutionizing the manufacturing of cell and gene therapies. These developments promise to shorten time-to-market and enhance treatment efficacy, while also presenting regulatory and ethical challenges.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
